284040-71-7

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-3-(2-HYDROXYETHOXY)-PYRIDINE is used as a building block in the synthesis of pharmaceuticals for its ability to undergo various chemical reactions and its bromine atom, which makes it useful for further derivatization.
Used in Agrochemical Industry:
5-BROMO-3-(2-HYDROXYETHOXY)-PYRIDINE is used as a building block in the synthesis of agrochemicals for its ability to undergo various chemical reactions and its bromine atom, which makes it useful for further derivatization.
Used in Organic Synthesis:
5-BROMO-3-(2-HYDROXYETHOXY)-PYRIDINE is used as a valuable intermediate in organic synthesis for its unique structure and reactivity, which make it a versatile chemical building block.

InChI:InChI=1/C7H8BrNO2/c8-6-3-7(5-9-4-6)11-2-1-10/h3-5,10H,1-2H2

Upstream product

• 74115-13-2 5-bromopyridine-3-ol 
• 105-58-8 Diethyl carbonate 
• 540-51-2 2-bromoethanol 
• 96-49-1 [1,3]-dioxolan-2-one 
• 2457-47-8 3,5-dichloropyridine 
• 107-21-1 ethylene glycol 

Relevant academic research and scientific papers

Carbazole and Carboline Compounds for Use in the Diagnosis, Treatment, Alleviation or Prevention of Disorders Associated with Amyloid or Amyloid-Like Proteins

The present invention relates to novel compounds that can be employed in the diagnosis, treatment, alleviation or prevention of a group of disorders and abnormalities associated with amyloid proteins and amyloid-like proteins, such as Alzheimer's disease. Precursors for the preparation of the compounds according to the present invention are also provided.

On both sides of the high-state metastatis hyperlipidemia Antialdosterone and having one side for diagnosis of the state of the radioactive pharmaceutical PET

A functional PET imaging method is disclosed for differentiation between bilateral hyperplasia and unilateral adenoma comprising (1) introducing a radioactively labelled CYP11 B2 (aldosterone synthase) inhibitor which binds selectively to CYP11 B2 (aldosterone synthase) relative to CYP11 B1 (112-hydroxylase) into a mammal with adrenal glands and (2) conducting positron emission tomography (PET) in the region of the adrenal glands to obtain a functional PET image of the adrenal glands. Also disclosed are radioactive tracer compounds suitable for use in this method, precursors for making the same, and a process for making the radioactive tracer compounds capable of being conducted as a rapid one-pot reaction.

PET radiopharmaceuticals for differential diagnosis between bilateral and unilateral conditions of primary hyperaldosteronism

A functional PET imaging method is disclosed for differentiation between bilateral hyperplasia and unilateral adenoma comprising (1) introducing a radioactively labelled CYP11 B2 (aldosterone synthase) inhibitor which binds selectively to CYP11 B2 (aldosterone synthase) relative to CYP11 B1 (11β-hydroxylase) into a mammal with adrenal glands and (2) conducting positron emission tomography (PET) in the region of the adrenal glands to obtain a functional PET image of the adrenal glands. Also disclosed are radioactive tracer compounds suitable for use in this method, precursors for making the same, and a process for making the radioactive tracer compounds capable of being conducted as a rapid one-pot reaction.

DERIVATIVES OF 2-[2-(BENZO- OR PYRIDO-) THIAZOLYLAMINO]-6-AMINOPYRIDINE, USEFUL IN THE TREATMENT OF RESPIRATORIC, ALLERGIC OR INFLAMMATORY DISEASES

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular Itk activity.

PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular ltk activity.

Novel potent ligands for the central nicotinic acetylcholine receptor: Synthesis, receptor binding, and 3D-QSAR analysis

In the past few years the focus on central acetylcholine receptors has shifted from-compounds with affinity for muscarinic acetylcholine receptors (mAChR) to compounds with affinity for nicotinic acetylcholine receptors (nAChR). The therapeutic potential